Opdivo-Yervoy (nivolumab-ipilimumab)

pCPA File Number: 23318

Negotiation Status:

Under consideration for negotiation

Indication(s):

For the first-line treatment of adult patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer.

Sponsor/Manufacturer:

Bristol Myers Squibb Canada Inc.

CDA-AMC Project Number:

PC0396-000

pCPA Engagement Letter Issued:

Not Applicable

Negotiation Process Concluded:

Not Applicable